Stockscreener 앱 받기
1.815
4.47%
-0.085
시간 외 거래:
1.82
0.005
+0.28%
전일 마감가:
$1.90
열려 있는:
$1.95
하루 거래량:
1.69M
Relative Volume:
0.61
시가총액:
$586.50M
수익:
$400.57M
순이익/손실:
$9.21M
주가수익비율:
45.38
EPS:
0.04
순현금흐름:
$146.36M
1주 성능:
-5.47%
1개월 성능:
-52.11%
6개월 성능:
-63.70%
1년 성능:
-88.01%
1일 변동 폭
$1.785
$1.99
1주일 범위
$1.785
$2.08
52주 변동 폭
$1.59
$15.26
아이언우드 제약 Stock (IRWD) Company Profile
명칭
Ironwood Pharmaceuticals Inc
전화
617-621-7722
주소
100 SUMMER STREET, SUITE 2300, BOSTON, MA
IRWD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
1.815 | 586.50M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
아이언우드 제약 Stock (IRWD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-09 | 개시 | Leerink Partners | Market Perform |
| 2024-08-08 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | 개시 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Wells Fargo | Overweight |
| 2023-11-09 | 개시 | Jefferies | Buy |
| 2023-09-28 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-02 | 개시 | CapitalOne | Overweight |
| 2022-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-09-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | 개시 | Northland Capital | Outperform |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-11-07 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-07-23 | 개시 | H.C. Wainwright | Sell |
| 2018-05-09 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2017-07-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2017-05-03 | 개시 | Wells Fargo | Outperform |
| 2017-04-07 | 재확인 | Mizuho | Buy |
| 2017-02-22 | 재확인 | Barclays | Equal Weight |
| 2016-11-04 | 재확인 | Mizuho | Buy |
| 2016-10-24 | 재확인 | Wedbush | Neutral |
| 2016-10-10 | 재확인 | Mizuho | Buy |
| 2016-09-27 | 재확인 | WallachBeth | Hold |
모두보기
아이언우드 제약 주식(IRWD)의 최신 뉴스
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Sees Large Growth in Short Interest - MarketBeat
Ironwood Pharmaceuticals Sets Key Date for 2024 Financial ResultsHere's When to Tune In - StockTitan
Ironwood Pharmaceuticals Inc (IRWD): A New Perspective - Stocks Register
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
FY2025 Earnings Forecast for IRWD Issued By Zacks Research - MarketBeat
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls - MSN
Zacks Research Issues Negative Forecast for IRWD Earnings - MarketBeat
What is Zacks Research’s Estimate for IRWD FY2025 Earnings? - Defense World
Michael Shetzline Sells 41,269 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Sells $244,752.64 in Stock - MarketBeat
Ironwood Pharmaceuticals (IRWD) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Insider Selling: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Insider Sells 12,048 Shares of Stock - MarketBeat
IRONWOOD PHARMACEUTICALS Earnings Preview: Recent $IRWD Insider Trading, Hedge Fund Activity, and More - Nasdaq
Ironwood Pharmaceuticals CEO Thomas A. McCourt sells $244,752 in stock - MSN
Zacks Research Issues Negative Outlook for IRWD Earnings - Defense World
11,869 Shares in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Acquired by SG Americas Securities LLC - Defense World
Ironwood Pharmaceuticals' principal accounting officer sells $21,204 in stock - MSN
Ironwood Pharmaceuticals' principal accounting officer sells $21,204 in stock By Investing.com - Investing.com Australia
Ironwood Pharmaceuticals CEO Thomas A. McCourt sells $244,752 in stock By Investing.com - Investing.com Australia
Ironwood Pharmaceuticals CFO sells shares worth $21,211 - MSN
Ironwood Pharmaceuticals chief legal officer sells shares worth $68,530 - MSN
Ironwood Pharmaceuticals chief legal officer sells shares worth $68,530 By Investing.com - Investing.com Nigeria
Ironwood Pharmaceuticals SVP sells shares worth $72,633 By Investing.com - Investing.com Australia
Ironwood Pharmaceuticals CFO sells shares worth $21,211 By Investing.com - Investing.com Australia
Ironwood Pharmaceuticals (IRWD) to Release Earnings on Thursday - Defense World
Ironwood Pharmaceuticals’ principal accounting officer sells $21,204 in stock By Investing.com - Investing.com Nigeria
Ironwood Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Could See Prices Soar In The Coming Months - Marketing Sentinel
Financial Health Report: Ironwood Pharmaceuticals Inc (IRWD)’s Ratios Tell a Tale - The Dwinnex
IRWD’s Stock Market Adventure: -61.63% YTD Growth Amidst Volatility - The InvestChronicle
Should You Invest in Ironwood Pharmaceuticals Inc (IRWD) Now? - The News Heater
Ironwood Pharmaceuticals stock falls as it exits S&P SmallCap 600 - MSN
Analysts Say Ironwood Pharmaceuticals Inc Can Reach $7 In 12 Months - Marketing Sentinel
Ironwood Pharmaceuticals Inc [IRWD] Stock trading around $1.94 per share: What’s Next? - The DBT News
Research Analysts Set Expectations for IRWD Q1 Earnings - MarketBeat
IRWD Shares Experience Decline in Value - Knox Daily
Ironwood Pharmaceuticals stock falls as it exits S&P SmallCap 600 By Investing.com - Investing.com Canada
STATE STREET CORP Reduces Stake in Ironwood Pharmaceuticals Inc - GuruFocus.com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Reaches New 1-Year Low Following Analyst Downgrade - MarketBeat
아이언우드 제약 (IRWD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.23%
3.94%
자본화:
|
볼륨(24시간):